- Daiichi Sankyo Company, LTD

QQQ $ 481.74 $ 2.81 (0.59 %)

DIA $ 391.56 $ 0.33 (0.08 %)

SPY $ 545.33 $ 1.12 (0.21 %)

TLT $ 90.13 $ -1.58 (-1.73 %)

GLD $ 215.59 $ 0.56 (0.26 %)

Previous Close

$ 33.6

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 23.72 - $ 37.72

Volume

72,389

Average Volume

Market Cap

Beta (5Y Monthly)

$ 0.61

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 1.01)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

fda-declines-to-approve-merck-daiichi-sankyo-partnered-lung-cancer-drug

FDA Declines To Approve Merck-Daiichi Sank...
06/27/2024 14:13:16

The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutat...

Reported Earlier, Daiichi Sankyo And Astra...
06/03/2024 06:49:46

DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody d...

why-is-astrazeneca-stock-trading-lower-on-tuesday

Why Is AstraZeneca Stock Trading Lower On ...
05/28/2024 18:32:38

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patient...

double-good-news-for-astrazenecas-breast-cancer-drugs

Double Good News For AstraZeneca's Breast ...
04/29/2024 13:25:58

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

astrazenecadaiichis-flagship-drug-enhertu-secures-accelerated-fda-approval-for-pretreated-cancer-patients-with-solid-tumor

AstraZeneca/Daiichi's Flagship Drug Enhert...
04/08/2024 14:34:33

FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated ...

Daiichi Sankyo And AstraZeneca's Datopotam...
04/02/2024 06:18:36

Daiichi Sankyo And AstraZeneca Announced E...
02/19/2024 15:56:25

Application based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab de...

Daiichi Sankyo And AstraZeneca's Supplemen...
01/29/2024 07:19:05

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data Submission to be reviewe...

What's Going On With Pfizer Stock Today?
01/25/2024 14:26:07

Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.

why-pharmaceutical-company-esperion-therapeutics-shares-are-diving-today

Why Pharmaceutical Company Esperion Therap...
01/03/2024 14:47:39

Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million ame...

The FDA Has Accepted And Granted Priority ...
12/22/2023 13:04:05

japan-emerges-as-promising-2024-investment-destination-3-stocks-to-consider

Japan Emerges As Promising 2024 Investment...
12/20/2023 13:38:11

Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outpe...

Daiichi Sankyo And Merck Announce Collabor...
10/20/2023 07:15:42

Financial Highlights Under the terms of the agreement, Merck will pay Daiichi Sankyo upfront payments of $1.5 billion for ifin...

better-than-chemotherapy---astrazenecadaiichi-sankyo-partnered-cancer-drug-meets-primary-goal-in-breast-cancer-setting

Better Than Chemotherapy - AstraZeneca/Dai...
09/22/2023 11:46:44

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:

AstraZeneca- Daiichi Sankyo's Datopotamab ...
09/22/2023 06:54:16

astrazenecas-reinforces-hold-in-lung-cancer-settings-touts-promising-data-from-three-trials

AstraZeneca's Reinforces Hold In Lung Canc...
09/11/2023 13:59:27

Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 pha...

AstraZeneca, Daiichi Sankyo's Datopotamab ...
09/11/2023 08:29:44

The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actiona...

fda-greenlights-daiichi-sankyos-blood-cancer-drug-a-promising-competitor-to-novartis-rydapt

FDA Greenlights Daiichi Sankyo's Blood Can...
07/21/2023 13:44:31

The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in

psyched-a-100m-donation-pledge-frank-biden-gets-candid-new-search-trends--more

Psyched: A $100M Donation Pledge, Frank Bi...
07/04/2023 14:21:01

World's Largest Psychedelics Conference Boasts 12K Attendees

astrazeneca-shares-under-pressure-on-some-adverse-events-in-late-stage-lung-cancer-drug-trial

AstraZeneca Shares Under Pressure On Some ...
07/03/2023 09:50:08

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato...

CLASS ACTION DEADLINES - JOIN NOW!

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/15/2024 UnitedHealth Group Inc. (UNH)

07/16/2024 Teladoc Health, Inc. (TDOC)

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Cambium Networks Corporation (CMBM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)

DSNKYDaiichi Sankyo Company, LTD

N/A

$ -0.94 (-2.72 %)